Investor Watch

SutroVax Closes $110 Million Series D to Advance Pneumonia Vaccine

SutroVax Closes $110 Million Series D to Advance Pneumonia Vaccine

SutroVax announced the closing of a $110 million Series D preferred stock financing to advance broadest spectrum pneumococcal vaccine candidates to prevent pneumonia in children and adults. The financing was co-led by new investors RA Capital Management and Janus...

Pin It on Pinterest